Investigating how FBXL16 contributes to breast cancer treatment resistance and spread
FBXL16 as a novel factor in promoting endocrine therapy resistance and metastasis of ER+ breast cancer
This study is looking at how a protein called FBXL16 influences estrogen receptor-positive breast cancer, especially why some patients don’t respond to hormone therapy and how the cancer might spread, with the goal of finding better treatment options for those facing advanced breast cancer.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wright State University NIH-funded |
| Lab location | 1 site (Dayton, United States) |
| Project ID | NIH-10794658 on NIH RePORTER |
What this research studies
This research focuses on understanding how the protein FBXL16 affects the behavior of estrogen receptor-positive (ER+) breast cancer, particularly in relation to resistance to endocrine therapy and the cancer's ability to spread. By examining the role of FBXL16 in stabilizing the estrogen receptor and its co-activators, the study aims to uncover new mechanisms that lead to treatment failure in patients. The researchers will conduct experiments to analyze the effects of FBXL16 on cancer cell behavior and response to therapy, which could provide insights into improving treatment strategies for patients with advanced breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced estrogen receptor-positive breast cancer who are experiencing resistance to current endocrine therapies.
Not a fit: Patients with early-stage breast cancer or those who do not have estrogen receptor-positive tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets that improve treatment outcomes for patients with ER+ breast cancer.
How similar studies have performed: While the specific role of FBXL16 in breast cancer is being explored, similar studies have shown that targeting protein interactions can lead to breakthroughs in understanding treatment resistance.
Where this research is happening
Dayton, United States
- Wright State University — Dayton, United States (Active)
Researchers
- Principal investigator: Long, Weiwen — Wright State University
- Study coordinator: Long, Weiwen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.